Since many patients appear to develop ACE2 antibodies after infection with SARS-CoV-2 but a smaller fraction develop long term symptoms, there may be differences in the ability of ACE2 autoantibodies to inhibit the enzymatic activity. The gene discussed is ACE2; the disease is infection.